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Mammalian target of rapamycin (mTOR, now referred to as mechanistic target of rapamycin) 
is considered as the master regulator of cell growth. A definition of cell growth is a build-up 
of cellular mass through the biosynthesis of macromolecules. mTOR regulation of cell 
growth and cell size is complex, involving tight regulation of both anabolic and catabolic 
processes. Upon a growth signal input, mTOR enhances a range of anabolic processes that 
coordinate the biosynthesis of macromolecules to build cellular biomass, while restricting 
catabolic processes such as autophagy. mTOR is highly dependent on the supply of 
nutrients and energy to promote cell growth, where the network of signalling pathways that 
influence mTOR activity ensures that energy and nutrient homeostasis are retained within 
the cell as they grow. As well as maintaining cell size, mTOR is fundamental in the 
regulation of organismal growth. This review examines the complexities of how mTOR 
complex 1 (mTORC1) enhances the cell’s capacity to synthesis de novo proteins required 
for cell growth. It also describes the discovery of mTORC1, the complexities of cell growth 
signalling involving nutrients and energy supply, as well as the multifaceted regulation of 
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1. Introduction 
1.1. History of Rapamycin and Drug Targets 
The background history of the discovery of mechanistic target of rapamycin (mTOR) is 
atypical. More commonly, small molecule kinase inhibitors are developed after discovery of 
the protein kinase. However, in the case of mTOR, this protein kinase was discovered 
through the drug activity of a naturally occurring inhibitor called rapamycin. Rapamycin (also 
known as sirolimus and later marketed under the trade name Rapamune by Pfizer) is a 
macrocyclic lactone isolated from Streptomyces hygroscopicus, a bacterium extracted from 
a soil sample on Easter Island (known as ‘Rapa-Nui’) [1]. The biosynthesis of rapamycin is 
an energy intensive multi-step process involving many multifunctional enzymes (reviewed in 
[2]). The bacteria acquire a selective advantage by synthesising and secreting rapamycin 
into the soil. Rapamycin has antifungal properties, enabling the bacteria to more easily 
colonise the soil by repressing the growth of competing fungi [3]. Originally defined as an 
antifungal compound in the mid-70s, rapamycin was later found to be effective as an 
immunosuppressant with anti-proliferative properties in humans [4,5]. 
While the drug property of rapamycin to impair growth was beginning to be realised, the drug 
target was unknown until the early 1990s. The first breakthrough into the mechanism of drug 
activity was the finding that rapamycin interacted with FKBP12 (FK506-binding protein 12), 
an immunophilin in mammalian cells (reviewed in [6]). Following on from this, research in 
yeast led to a series of pivotal discoveries. By using FK506 columns, the yeast FKBP 
(FK506-binding protein) was purified and was identified as FK506-binding protein 1 (FRR1) 
[7]. Surprisingly, yeast genetics revealed that FRR1 was not involved in controlling cell 
growth. This was because genetic loss of FRR1 did not arrest growth like rapamycin, 
implying that there had to be another drug target of rapamycin [4,7,8]. To identify this elusive 
drug target, genetic screens in yeast were carried out for rapamycin-resistant mutants [7,9]. 
These genetic screens did not only reveal FRR1, but also discovered two genes that were 
accordingly named as target of rapamycin 1 (TOR1) and TOR2. Disruption of both TOR1 
and TOR2 phenocopied rapamycin to cause cell growth arrest in yeast [10]. From these 
early studies, it was ascertained that rapamycin acted on TOR1 and TOR2 to repress cell 
growth. However, the other piece of the puzzle involving rapamycin-FRR1 (as a drug-
immunophilin complex) was not yet recognised. For some drug-immunophilin complexes, 
drug association with an immunophilin results in adding an additional drug activity, which is 
observed when cyclosporine A interacts with FK506 [6]. Therefore, it was speculated that 
rapamycin might gain a new drug activity to arrest cell growth when associated with an 
FKBP. Substantiating this idea, the rapamycin-FRR1 complex in yeast was later found to 
bind directly to TOR1 and TOR2 to arrest cell growth [11,12,13]. In mammalian systems, it 
was also observed that a homologous protein to yeast TOR1 and TOR2 directly interacted 
with FKBP12-rapamycin [14,15], which was later called mTOR. By the mid-1990’s, the drug 
activity of rapamycin was better understood; rapamycin could bind to and inhibit TOR as a 
rapamycin-FKBP drug-immunophilin complex. In yeast, loss of TOR1 and TOR2 
phenocopies nutrient starvation to cause inhibition of protein synthesis, glycogen 
accumulation and autophagy induction [16,17,18,19]). Since these early yeast studies, much 
has been discovered, including delineation of the mTOR signalling network and conservation 
of this pathway in higher eukaryotic cells. 
1.2. mTOR Structure and Protein Complexes 
mTOR is a member of the phosphatidylinositol 3-kinase-related kinases (PIKK) family, which 
includes DNA-dependent protein kinase (DNA-PK, also known as protein kinase, DNA-
activated, catalytic polypeptide), ATM serine/threonine kinase (ATM) and ATR 
serine/threonine kinase (ATR). Instead of having lipid kinase activity, mTOR’s kinase 
catalytic domain functions to phosphorylate proteins on Ser/Thr residues [15,20]. 
Distinguishing features of mTOR include multiple HEAT (Huntington, EF3, A subunit of 
PP2A, TOR1) repeats within the N-terminus that permits multiple protein-protein interactions 
[21]. mTOR also possesses a central FAT (FRAP, ATM, TRAP) domain and a C-terminal 
FAT (FATC) domain that are also conserved in other PIKK family members [22]. Allosteric 
interaction of FKBP12-rapamycin with the FKBP-rapamycin binding (FRB) domain is 
inhibitory to the phosphotransferase activity of mTOR. The FRB domain is situated between 
the central FAT and the kinase domain [11,14]. 
While yeast possesses two TOR genes, there is only one mTOR gene in higher eukaryotes. 
Rather than gene duplication as an evolutionary route to generate two distinctive TOR 
protein kinases as observed in yeast, higher eukaryotes instead possess a single mTOR 
gene that becomes integral to two protein kinase complexes, called mTOR complex 1 
(mTORC1) and mTORC2. Both mTORC1 and mTORC2 are high molecular weight protein 
complexes that contain an array of core binding and regulatory proteins that are associated 
with the mTOR catalytic subunit. mTORC1 was first identified by the association of mTOR 
with rapamycin-associated protein of TOR (Raptor) [23,24] and MTOR associated protein, 
LST8 homolog (mLST8) [25]. Raptor functions as a scaffold protein and it’s binding to mTOR 
is necessary for mTORC1 substrate specificity (reviewed in [26]). mTORC1 also interacts 
with regulatory proteins that inhibit mTORC1, proline-rich Akt substrate of 40 kDa (PRAS40) 
[27,28,29] and DEP domain containing mTOR-interacting protein (DEPTOR) [30]. Other 
regulatory mTORC1 interacting proteins include the telomere maintenance 2 (TELO2) and 
TELO2 interacting protein 1 (TTI1), which associates with mTORC1 as a TELO2/TTI1 
complex and is necessary for mTORC1 assembly [31]. For mTORC2, mLST8 and DEPTOR 
also interact. Core binding subunits that are exclusive to mTORC2 include rapamycin-
insensitive companion of mammalian target of rapamycin (Rictor), mSin1 (mammalian 
stress-activated protein kinase interacting protein 1) and Protor (protein observed with 
Rictor-1) [32,33]. Rictor is essential for substrate specificity of mTORC2 as well as its 
assembly and stability, while mSin1 functions as a negative regulator (reviewed in [34]). 
mTORC2 is a regulator of the cytoskeleton through its stimulation of F-actin stress fibers. 
mTORC2 directly phosphorylates and activates AKT to enhance cell growth via mTORC1. 
As mTORC1 is more centrally involved in the control of cell growth when compared to 
mTORC2, this review focuses mainly on mTORC1-regulated processes. 
mTORC1 and mTORC2 can be distinguished by their differences in rapamycin sensitivity. 
Prior to the discovery of the two mTOR complexes, it was commonly presumed that 
rapamycin was effective at blocking the kinase activity of mTOR. However, the kinase 
activity of mTORC2 is insensitive to rapamycin, which was the principle reason why 
mTORC2-driven processes remained hidden in earlier studies that employed rapamycin. 
Furthermore, it is now appreciated that some mTORC1-mediated phosphorylation events 
are partially resistant to rapamycin [35,36]. As an example, mTORC1-mediated 
phosphorylation of a well-characterised mTORC1 substrate, eukaryotic initiation factor-4E-
binding protein 1 (4E-BP1) at Thr37/Thr46 is heavily resistant to rapamycin treatment [37]. 
Another partially rapamycin resistant process that is regulated by mTORC1 is autophagy, 
where the level of resistance varies depending on cell-type [36]. It was hypothesised that 
cells with a more open (or relaxed) mTORC1 conformation would likely have higher 
sensitivity to rapamycin [36]. For mTORC2, short-term rapamycin treatment is not inhibitory. 
However, longer durations of treatment can indirectly inhibit mTORC2. This is because 
rapamycin-FKBP12 associates with newly synthesised mTOR prior to complex assembly, 
sequestering this “free pool” of mTOR from Rictor to prevent mTORC2 formation. 
Consequently, prolonged treatments of rapamycin (over days of treatment) can indirectly 
lead to reduced mTORC2 activity [38]. 
Rapamycin has been instrumental in the discovery of mTOR and has helped elucidate 
rapamycin sensitive cell processes that were later found to be driven by mTORC1. However, 
with the introduction of gene silencing and targeted genomic editing technologies, a much 
greater appreciation of mTORC1 and mTORC2 is beginning to emerge, where knockdown 
or knockout of either Raptor or Rictor is now more frequently used to ablate mTORC1 or 
mTORC2 signal transduction, respectively. Furthermore, the introduction of ATP-competitive 
inhibitors of mTOR adds an additional research tool, allowing researchers to more fully 
repress the kinase activity of both mTOR complexes.  
2. mTORC1 and Cell Growth Control 
2.1. Upstream Signalling Pathway of mTORC1 
Model systems such as Drosophila have been instrumental in understanding the role that 
mTOR has in cell growth control and organismal size. Genetic analysis of the Drosophila 
TOR homolog, dTOR (also now being referred to as mTOR), clearly revealed that 
inactivating mTOR mutations cause a delay in cell proliferation and reduce cell size [39]. 
While conversely, mTOR activation promoted cell and organ size [39]. Another key discovery 
made was the identification of the Drosophila genes dTSC1 (Tuberous sclerosis complex 1) 
and dTSC2 as regulators of cell size [40,41,42]. Genetic epistasis experiments uncovered 
that dTSC1 and dTSC2 functioned as negative regulators of cell size, positioning them 
downstream of the insulin receptor and AKT (AKT serine/threonine kinase) [40,41]. These 
genetic studies positioned Drosophila ribosomal protein S6 kinase (dS6K) downstream of 
dTSC1 and dTSC2. In fruit flies, dS6K controls cell size, where dS6K inactivation mutations 
cause a small fly phenotype [43]. dS6K, as well the mammalian homologue, ribosomal 
protein S6 kinase 1 (S6K1) are well-characterised rapamycin-sensitive substrates of 
mTORC1 [44]. These fly studies inferred that dTSC1 and dTSC2 functioned upstream of 
mTORC1. Sequential studies confirmed that dTSC1/dTSC2 were genetically positioned 
upstream from mTOR. Inactivation mutations of mTOR blocked the large cell phenotype in 
dTsc2 mutant flies [45]. Furthermore, mutations reducing the activity of mTOR and dS6K 
rescued the lethality caused by dTSC1 mutations [42]. Therefore, it was discovered that 
dTSC1 and dTSC2 functioned to repress growth signals upstream of mTORC1. 
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic condition caused by 
loss of function mutations in either TSC1 or TSC2. TSC1 and TSC2 are tumour suppressors 
that function together, where loss of function mutations of either gene predisposes the 
growth of tumours in multiple organs in TSC patients, including the kidney, brain and skin, as 
well as neurocognitive problems and epilepsy [46]. Tumour growth in TSC patients is now 
known to be dependent on mTORC1. Consequently, primary care to treat TSC patients 
include the use of mTORC1 inhibitors, such as everolimus [46]. Basic research showing the 
involvement of TSC1/TSC2 in mTORC1 signal transduction followed by rapamycin pre-
clinical studies in mouse models of TSC [47] were instrumental in the repositioning of 
mTORC1 inhibitors to treat TSC. Basic research that followed on from the genetic analysis in 
Drosophila described above revealed a conserved pathway in mammals. Within the 
phosphatidylinositide 3-kinase (PI3K)/AKT signalling pathway, AKT directly phosphorylates 
TSC2 on four or five residues, revealing that TSC1/TSC2 is directly regulated by AKT 
[48,49,50]. Over-expression of TSC1 and TSC2 also markedly inhibited S6K1, positioning 
TSC1/TSC2 upstream of S6K1. TSC1/TSC2 was then later shown to repress signal 
transduction through mTORC1 [51]. It was assumed that a small-G protein was likely 
regulated by TSC1/TSC2, as TSC2 (also known as tuberin) possessed a conserved C-
terminal GTPase activating protein (GAP) domain that was commonly lost in TSC patients 
(via C-terminal truncating point-nonsense mutations) [52,53]. Furthermore, a cluster of 
pathogenic single point mutations within the conserved GAP domain of TSC2 was also 
reported [53]. In yeast, a likely small G-protein candidate was Ras homologue enriched in 
brain (Rheb), where genetic loss of Rheb in yeast phenocopied nutrient starvation [54]. 
Confirming the involvement of this small G protein, Rheb was found to be regulated by 
TSC1/TSC2 in mammalian cells [55,56,57]. When complexed with TSC1, TSC2 functions as 
a Rheb GAP, switching Rheb to an inactive GDP-bound form to turn mTORC1 off [57]. Rheb 
becomes activated, i.e., GTP-loaded, when the TSC1/TSC2 complex is repressed through 
an array of upstream kinases within mitogenic and hormone stimulated pathways (depicted 
in Figure 1). Paralleling the PI3K/AKT pathway, mitogen-activated protein kinases (MAPK) 
also converges on TSC1/TSC2 to positively regulate mTORC1 [58]. It was later found that 


















Figure 1. mTORC1 signal transduction and tumour suppressors. Growth signals via plasma 
membrane bound receptors activate the Ras/Raf/MAPK/ERK/RSK and PI3K/AKT signalling 
pathways. Tumour suppressors upstream of TSC1/TSC2 include PTEN and LKB1 (indicated 
in red). Through these pathways, TSC1/TSC2 is inactivated, converting Rheb to an active 
GTP-bound state to promote mTORC1 (when associated with the “Ragulator complex” on 
lysosomal membranes). When nutrients are sufficient, Rag GTPase heterodimers recruit 
mTORC1 to the “Ragulator complex”. Arginine inhibits both TSC1/TSC2 and CASTOR. 
Leucine activates GATOR2 indirectly via sestrins. Under energy deprivation, LKB1/AMPK 
activates TSC1/TSC2 to switch mTORC1 off. mTORC1 drives cell growth (in part) by 
increasing the efficiency of mRNA translation of mTORC1-sensitive mRNAs (that include 
MYC and CCND1). mTORC1 regulates protein synthesis via 4E-BP1/eIF4E and S6K1.  
2.2. Regulation of Protein Translation and Cell Growth by mTORC1 
mTORC1 relays nutrient, energy and growth signals to drive cell growth through promotion 
of anabolic processes such as protein synthesis. As well as enhancing the efficiency of 
protein translation, mTORC1 promotes protein translation through increasing the production 
of ribosomes. Furthermore, mTORC1 boosts the generation of nucleotide precursors that 
are essential for a growing cell. These nucleotide precursors are required for the generation 
of rRNA to build new ribosomes, mRNA to be transcribed into proteins necessary for growth 
and dNTP nucleotides for DNA replication during cell division. 
mTORC1 regulates protein translation through an array of translation factors that include 4E-
BP1 and S6K1. Both 4E-BP1 and S6K1 possess an mTORC1 signalling (TOS) motif, which 
associates with Raptor [61]. Consequently, the TOS motif is necessary for the recruitment of 
both 4E-BP1 and S6K1 to mTORC1 and the phosphorylation of these substrates [61]. 4E-
BP1 acts as a negative regulator of cap-dependant protein translation. eukaryotic initiation 
factor (eIF) 4E associates with the m7GpppN cap moiety on the 5′-end of mRNAs and is 
inactivated through association with 4E-BP1 when in an unphosphorylated state, thus 
preventing the translation of mRNAs involved in cell growth [62]. mTORC1 phosphorylates 
4E-BP1 on four Ser/Thr residues, causing dissociation of 4E-BP1 from eIF4E. As 
association of either 4E-BP1 or eIF4G to eIF4E are mutually exclusive, eIF4G then 
associates with eIF4E to promote translation initiation (reviewed in [21]). eIF4G acts as a 
scaffold to recruit other translation initiation factors, such as eIF4A, to form the eIF4F 
complex. Assembly of eIF4F is considered a rate-limiting step of translation initiation. As part 
of the eIF4F complex, eIF4A has RNA helicase activity that unwinds the secondary structure 
within the 5′-untranslated region (5′-UTR) of the mRNA to help the efficacy of ribosome 
scanning to the start codon. Via mTORC1, S6K1 further enhances the RNA helicase activity 
of eIF4A by phosphorylating eIF4B on Ser422 [63]. mRNAs involved in cell growth are 
heavily dependent on mTORC1. The length and degree of secondary structure within the 5’-
UTR contributes to the dependency of these mRNAs to mTORC1 and the availability of 
eIF4F (reviewed in [64]). Examples of mRNAs involved in cell growth that are highly 
dependent on eIF4F include the MYC proto-oncogene, bHLH transcription factor (MYC) and 
cyclin D1 (CCND1) [65]. 
2.3. Ribosomal Biogenesis and mTORC1 
The cells’ capacity to generate protein is limited by the number of ribosomes they have. 
Consequently, mTORC1 promotes ribosomal biogenesis to ensure rapid growth. Typically, 
5′-terminal oligopyrimidine (5′-TOP) tracts are found in mRNA that encode for factors 
involved in ribosomal biogenesis and ribosomal proteins [66,67]. These 5′-TOP tracts 
function as translational cis-regulatory elements. 5′-TOP mRNAs are sensitive to rapamycin 
and are found to be dependent on S6K1 [68]. Over 75% of the proteins involved in ribosomal 
biogenesis are estimated to be controlled by S6K1 [68]. In a recent study, high resolution 
ribosomal profiling identified 144 mRNAs that were sensitive to mTORC1 inhibitors [69]. 
Only 68% of these mRNAs possessed putative 5′-TOP tracts, while 63% contained a newly 
discovered cis-regulatory pyrimidine-rich translational element (PRTE). Rather than being 
dependent on S6K1, PRTE mRNAs were found to be highly sensitive to 4E-BP1. Many of 
the mTORC1-sensitive target genes uncovered by Hsieh et al., were ribosomal proteins [69], 
which highlights the critical involvement of mTORC1 in the generation of new ribosomes. 
The regulatory mechanism of these translational cis-regulatory elements is currently 
unknown. Presumably, trans-acting factors bind to these elements and regulate the 
translation of the mRNA. Several potential trans-acting factors that bind to the 5′-TOP have 
been studied to date that include the La protein [70] and the La-related proteins (LARP) 
[71,72,73]. 
mTORC1 also promotes the generation of rRNA. rRNAs are the major component of the 
ribosome that comprise of 60% of the ribosomal mass. Eukaryotic ribosomes consist of four 
rRNAs called the 5S, 5.8S, 18S and 28S. RNA polymerase I (Pol I) transcribes a precursor 
47S pre-rRNA that is sequentially processed in the nucleoli to form the mature 5.8S, 18S 
and 28S rRNA species. The 5S rRNA is generated by Pol III, which is also involved in the 
formation of transfer RNA (tRNA). To further enhance the production of rRNA, mTORC1 
activates both Pol I and Pol III via several mechanisms. mTORC1 directly phosphorylates 
Transcription Initiation Factor I (TIF1A) to cause its translocation to the nucleolus and 
activation of Pol I [74]. mTORC1 further promotes Pol I via S6K1. S6K1 phosphorylates 
Upstream Binding Factor (UBF), causing UBF-TIF1B interaction and Pol I activation [75]. 
Through Pol I, mTORC1 and S6K1 enhance the production of 5.8S, 18S and 28S rRNA. 
mTORC1 also enhances the production of the 5S rRNA species by phosphorylating and 
inhibiting a negative regulator of Pol III, called MAF1 (MAF1 homolog, negative regulator of 
RNA polymerase III) [76]. In another study, mTORC1 was shown to directly bind to the 
promoter region of Pol I and Pol III, leading to their enhanced gene-expression [77]. 
Therefore, mTORC1-dependent regulation of ribosomal proteins and rRNA during ribosomal 
biogenesis is multifaceted. 
To ensure that there is a sufficient supply of nucleotides for the generation of rRNA, 
mTORC1 promotes the production of nucleotide precursors. mTORC1 does this by 
redirecting glucose metabolites into the pentose phosphate pathway. The pentose 
phosphate pathway generates nicotinamide adenine dinucleotide phosphate, ribose-5-
phosphate and erythrose-4-phosphate, precursors for fatty acids, nucleotides and aromatic 
amino acids, respectively. Generation of fatty acids, nucleotides and aromatic amino acids 
are essential for a growing cell, i.e., for the expansion of membranes and the de novo 
synthesis of mRNA, rRNA, DNA, and proteins. Carbamoyl-phosphate synthetase 2, 
aspartate transcarbamylase, and dihydroorotase (CAD) within the pentose phosphate 
pathway was found to be phosphorylated and activated by S6K1 [78]. CAD catalyses the 
first three enzymatic steps of a six-step pyrimidine biosynthesis pathway to enrich the 
pyrimidine nucleotide pool [78]. More recently, mTORC1 was found to enhance purine 
biosynthesis through ATF4-mediated gene-expression of methylenetetrahydrofolate 
dehydrogenase 2 (MTHFD2), a metabolic enzyme involved in the synthesis of purine 
nucleotides [79]. In this study, it was found that mTORC1 increased the protein translation of 
ATF4, the transcription factor that drives the gene-expression of MTHFD2.  
3. Nutrient and Energy Homeostasis during Cell Growth 
Cell growth is tightly controlled by both nutrient and energy supply. If the supply of either 
nutrients or energy is insufficient, feedback mechanisms ensure that mTORC1 is switched 
off. Such signalling mechanisms maintain energy and nutrient homeostasis during cell 
growth. 
3.1. Nutrient Signalling and mTORC1 
Early studies implicated that mTORC1 required the presence of branch-chained amino acids 
for its full activation (reviewed in [80]). However, it was unclear how nutrients were “sensed” 
by mTORC1. The first indication that mTORC1 sensed an intracellular amino acid pool were 
in experiments that utilised cycloheximide, a drug that blocks translation elongation [81]. The 
amino acid reserves of a cell can become quickly exhausted via protein translation. 
Therefore, inhibition of protein translation with cycloheximide can be used to help indirectly 
replenish the intracellular amino acid stores. It was found that increasing the pool of 
intracellular amino acids after cyclohexmide treatment was sufficient to activate mTORC1 in 
the absence of external amino acid supply or growth factor stimuli [81]. It is now appreciated 
that intracellular nutrient sensing occurs at the level of lysosomes. In summary, Rag GTPase 
heterodimers regulate the localisation of mTORC1 to lysosomes [82,83]. During amino acid 
sufficiency, active Rag heterodimers (consisting of either RagA-GTP or RagB-GTP bound to 
either RagC-GDP or RagD-GDP) will associate with Raptor. These active Rag heterodimers 
bound to Raptor then translocate mTORC1 to the “Ragulator complex” found on the 
membrane surface of lysosomes, which is necessary for mTORC1 activation [84]. Under 
conditions of nutrient withdrawal, mTORC1 is cytoplasmically localised and is inactive. The 
Rag proteins are regulated by the Ragulator complex that is comprised of five proteins 
referred to as the late endosomal/lysosomal adaptor, MAPK and mTOR activator 1-5 
(LAMTOR1-5) [84]. The Ragulator complex acts as a guanine nucleotide exchange factor 
(GEF) towards RagA and RagB, switching them to an active GTP-bound state [85]. RagA 
and RagB are negatively regulated by RagGTPases and GTRs-1 (GATOR) and GATOR2, 
that are also lysosomally localised [86]. GATOR1 acts as a RagGAP, switching both RagA 
and RagB to an inactive GDP-bound state to prevent lysosomal localisation of mTORC1 (to 
turn off mTORC1 signalling). GATOR2 lies directly upstream of GATOR1 and functions as a 
negative regulator of GATOR1. GATOR2 is positively regulated by nutrients [86]. 
Leucine was proposed to be sensed by three sestrins (SESN1-3) that activate GATOR2, 
which then in turn inactivates GATOR1 to switch the Rag heterodimers to an active state 
and promote mTORC1 signalling [87,88]. However, there is some controversy regarding 
SESN1-3 as a direct leucine sensor (reviewed in [89]). This is due to the known function of 
SESN1-3 to activate AMPK during cell stress [90,91,92]. Activation of AMPK can indirectly 
turn off mTORC1 (via a signalling feedback mechanism involving TSC1/2 that is summarised 
in Section 3.2 below). Indeed, genetic evidence in SESN-deficient fly and mouse models 
infer that the overriding function of SESN is to activate AMPK and to inhibit mTORC1, which 
importantly can occur in the presence of physiological levels of leucine [90,91,92]. It is 
possible that leucine is sensed by Leucyl-tRNA synthetase at the lysosome instead, which 
has been shown to function as a GAP towards RagD [93]. 
Arginine is sensed by mTORC1 via several mechanisms. It was recently found that TSC1/2 
associates with Rheb when arginine levels are low, which causes TSC1/2 to switch Rheb to 
an inactive GDP-bound state to inhibit mTORC1 [94]. As another mechanism of arginine 
sensing, cytosolic arginine sensor for mTORC1 (CASTOR) subunit 1 interacts with GATOR2 
in the absence of arginine to prevent mTORC1 activation [95]. When arginine levels are in 
sufficient supply, arginine binds to CASTOR1 to displace GATOR2 from the inhibited 
CASTOR1-CATOR2 complex. Consequently, GATOR2 is then able to turn off GATOR1, 
leading to mTORC1 activation [95]. Further studies in animal models will be required to 
validate these nutrient sensing mechanisms. 
Evidently, nutrient sensing by mTORC1 is complex and involves multiple inputs. In the 
context of growth control, leucine is well known to play a significant role in the determination 
of muscle mass involving mTORC1. Leucine accounts for about 20% of our dietary protein 
intake and branch-chained amino acids account for about a third of muscle protein [96]. 
Muscle is the primary reservoir of protein within the human body. Therefore, it is not 
surprising that muscle cells are subjected to particularly high levels of protein turnover rates 
that help maintain amino acid homeostasis within the whole body. Leucine is critical for 
driving muscle growth and does this, in part, through the activation of mTORC1. Resistance 
exercise with protein supplements (including leucine) can promote the build-up of muscle 
mass [97]. Through activation of mTORC1, leucine is a potent activator of protein synthesis 
that drives anabolic muscle growth. 
Nutrient withdrawal is known to restrict organ size and implicates the mTORC1 pathway and 
nutrient sensing in organismal growth. Growth regulation of organs is complex, involving 
multiple pathways that coordinates cell number (via the control of proliferation and 
apoptosis) and cell size. It is appreciated that mTORC1 works alongside the Hippo pathway 
to coordinate organ growth (reviewed in [98]). The transcription factor yes-associated protein 
1 (YAP1) is activated in the Hippo pathway to drive gene-expression of CCND1 and Myc, 
which are involved in proliferation and cell size control, respectively. It is interesting that the 
protein translation of CCND1 and Myc mRNAs are mTORC1-dependent (Figure 1, and [65]). 
As a consequence, the Hippo and mTORC1 pathways would appear to work jointly to 
enhance organ growth by enhancing the transcriptional and translational regulation of 
CCND1 and Myc. 
3.2. Energy Signalling and mTORC1 
The anabolic processes needed for cellular growth are dependent on energy as well as 
nutrients, so mTORC1 enhances mitochondrial biogenesis to generate more mitochondria 
[99], ensuring that the cell has enough capacity to generate energy as the cell grows. The 
ability of mTORC1 to switch between states of anabolic growth and catabolic fasting is 
dynamically regulated and is intrinsically coupled with the energy senor, AMP-dependant 
protein kinase (AMPK). A major catabolic process that AMPK regulates is autophagy 
(reviewed in [100]). In the disease setting, improper mTORC1 signalling leads to 
uncontrolled cell growth and loss of energy homeostasis. Energy stress, through activation 
of AMPK is also upstream of TSC1/TSC2, where AMPK-dependent phosphorylation of TSC2 
on Thr1227 and Ser1345 activates the TSC1/TSC2 tumour suppressor, leading to mTORC1 
inhibition [101]. AMPK also phosphorylates Raptor, which is also inhibitory to mTORC1 
[102]. AMPK becomes active when ATP levels decline and AMP levels increase. Upon 
energy stress, AMPK is activated by the serine/threonine kinase LKB1/STK11 [103,104]. 
Inactivating mutations of LKB1 inhibits AMPK and can give rise to Peutz-Jeghers syndrome 
that predisposes patients to hamartomatous polyps and cancer in the gastrointestinal tract 
[105]. As cells require a plentiful supply of energy to grow efficiently, this negative signalling 
input from AMPK ensures that cell growth through mTORC1 is halted when energy supply is 
insufficient. To quickly restore energy balance within the cell, AMPK not only downregulates 
anabolic processes driven by mTORC1, but also enhances catabolic processes, such as 
autophagy. 
4. Conclusions 
Since the discovery of rapamycin, much has been learnt about its drug target, mTORC1, and 
the role it plays in cell growth control. mTORC1 is regulated at the level of lysosomes, where 
multiple signalling inputs from growth factor (and hormone) receptors as well as from 
nutrients and energy all converge onto mTORC1. Coordination of such signalling inputs 
ensures that the homeostatic balance of nutrients and energy is maintained as a cell grows. 
The capacity of a cell to manufacture de novo proteins is rate limiting in cell growth, which is 
why the regulation of protein synthesis by mTORC1 is multifaceted through ribosomal 
biogenesis, generation of nucleotide precursors, and the regulation of protein translation. 
mTORC1 signalling is clearly tightly integrated with metabolism, but there is still much to 
understand. The nuclear function of mTORC1 is also currently unknown. Underdeveloped 
areas of research involving mTORC1 includes chromosomal remodelling and the regulation 
of transcription factors linked to cell growth control. mTORC1 is also implicated in mRNA 
splicing that adds another layer of regulation [106]. Clearly, there is still much to be 
discovered regarding how mTORC1 ‘mechanistically’ controls cell growth. 
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